Ivor B Asztalos1, Joi A Gleason1, Sakine Sever2, Reyhan Gedik2, Bela F Asztalos3, Katalin V Horvath3, Michael L Dansinger4, Stefania Lamon-Fava3, Ernst J Schaefer5. 1. Cardiovascular Research Associates, Boston, MA, USA; Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA. 2. Cardiovascular Research Associates, Boston, MA, USA. 3. Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA. 4. Cardiovascular Research Associates, Boston, MA, USA; Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA; Division of Endocrinology and Metabolism, Tufts Medical Center, Boston, MA, USA. 5. Cardiovascular Research Associates, Boston, MA, USA; Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA. Electronic address: ernst.schaefer@tufts.edu.
Abstract
BACKGROUND:Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the primary omega-3 fatty acids in fish oil, have been shown to reduce cardiovascular disease (CVD) risk. OBJECTIVE: This study aimed to examine the independent effects of EPA and DHA on lipid and apolipoprotein levels, as well as on inflammatory biomarkers of CVD risk, using doses often used in the general population. DESIGN: A blinded, randomized 6-week trial was performed in 121 healthy, normolipidemic subjects who receivedolive oil placebo 6g/d, EPA 600mg/d, EPA 1800mg/d, or DHA 600mg/d. The EPA was derived from genetically modified yeast. RESULTS: The subjects tolerated the supplements well with no safety issues; and the expected treatment-specific increases in plasma EPA and DHA levels were observed. Compared to placebo, the DHA group had significant decreases in postprandial triglyceride (TG) concentrations (-20%, -52.2mg/dL, P=0.03), significant increases in fasting and postprandial low-density lipoprotein cholesterol (LDL-C) (+18.4%, 17.1mg/dL, P=0.001), with no significant changes in inflammatory biomarkers. No significant effects were observed in the EPA 600mg/d group. The high-dose EPA group had significant decreases in lipoprotein-associated phospholipase A2 concentrations (Lp-PLA2) (-14.1%, -21.4ng/mL, P=0.003). CONCLUSIONS: The beneficial effects of EPA 1800mg/d on CVD risk reduction may relate in part to the lowering of Lp-PLA2 without adversely affecting LDL-C. In contrast, DHA decreased postprandial TG, but raised LDL-C. Our observations indicate that these dietary fatty acids have divergent effects on cardiovascular risk markers.
RCT Entities:
BACKGROUND:Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the primary omega-3 fatty acids in fish oil, have been shown to reduce cardiovascular disease (CVD) risk. OBJECTIVE: This study aimed to examine the independent effects of EPA and DHA on lipid and apolipoprotein levels, as well as on inflammatory biomarkers of CVD risk, using doses often used in the general population. DESIGN: A blinded, randomized 6-week trial was performed in 121 healthy, normolipidemic subjects who received olive oil placebo 6g/d, EPA 600mg/d, EPA 1800mg/d, or DHA 600mg/d. The EPA was derived from genetically modified yeast. RESULTS: The subjects tolerated the supplements well with no safety issues; and the expected treatment-specific increases in plasma EPA and DHA levels were observed. Compared to placebo, the DHA group had significant decreases in postprandial triglyceride (TG) concentrations (-20%, -52.2mg/dL, P=0.03), significant increases in fasting and postprandial low-density lipoprotein cholesterol (LDL-C) (+18.4%, 17.1mg/dL, P=0.001), with no significant changes in inflammatory biomarkers. No significant effects were observed in the EPA 600mg/d group. The high-dose EPA group had significant decreases in lipoprotein-associated phospholipase A2 concentrations (Lp-PLA2) (-14.1%, -21.4ng/mL, P=0.003). CONCLUSIONS: The beneficial effects of EPA 1800mg/d on CVD risk reduction may relate in part to the lowering of Lp-PLA2 without adversely affecting LDL-C. In contrast, DHA decreased postprandial TG, but raised LDL-C. Our observations indicate that these dietary fatty acids have divergent effects on cardiovascular risk markers.
Authors: Stephen R Wassall; Xiaoling Leng; Samuel W Canner; Edward Ross Pennington; Jacob J Kinnun; Andres T Cavazos; Sahil Dadoo; Dylan Johnson; Frederick A Heberle; John Katsaras; Saame Raza Shaikh Journal: Biochim Biophys Acta Biomembr Date: 2018-05-03 Impact factor: 3.747
Authors: Denisa Margină; Anca Ungurianu; Carmen Purdel; George Mihai Nițulescu; Dimitris Tsoukalas; Evangelia Sarandi; Maria Thanasoula; Tatyana I Burykina; Fotis Tekos; Aleksandra Buha; Dragana Nikitovic; Demetrios Kouretas; Aristidis Michael Tsatsakis Journal: Food Chem Toxicol Date: 2020-07-05 Impact factor: 6.023
Authors: Ivan M Petyaev; Natalya E Chalyk; Victor A Klochkov; Dmitry V Pristensky; Marina P Chernyshova; Nigel H Kyle; Yuriy K Bashmakov Journal: Int J Appl Basic Med Res Date: 2018 Jul-Sep